Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Co-administered Cilostazol and Rosuvastatin
NCT06568133Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cilostazol and rosuvastatin in Peripheral Arterial Disease (PAD) and hypercholesterolemia (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve at Steady State over Dosing Interval at Day 21 and Maximum Plasma Concentration at Steady State at Day 21. Started Mar 2017; status: completed.
02
Drugs
cilostazolrosuvastatin
03
Conditions
Peripheral Arterial Disease (PAD)hypercholesterolemia
Beyond the preview
Go deeper on NCT06568133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568133.